On 2 Oct 2026, PATEO (02889.HK) completed the acquisition of a ~70% stake; the target was valued at RMB2.7bn with consideration capped at RMB1.4bn.
On 2 Oct 2026, WK GROUP (02535.HK) and WellLuck said the mandatory cash offer lapsed as conditions were unmet, with only 30,000 shares (0.0015%) accepted.
On 2 October 2026, GoFintech Quantum Innovation Limited (00290.HK) announced that its Fortune Asset Management Open-ended Fund Company and its two publicly offered sub-funds (the Fortune Asset Technology Select Equity Fund and the Fortune Asset Fixed Income Fund) were approved by the Securities and Futures Commission of Hong Kong on 30 September 2026.
On 2 October 2026, Ascletis Pharma Inc. (01672.HK) announced that key preclinical data for ASC36_35FDC were presented at the 62nd Annual Meeting of the European Association for the Study of Diabete.
As of October 2, 2026, Global X China Semiconductor ETF (03191.HK) fell 5.19% intraday to a latest price of HK$76.320, with a turnover of HK$32.2959 million; the ETF is managed by Mirae Asset Global Investments (Hong Kong) Limited and tracks the FactSet China Semiconductor Index (Net Total Return), with assets under management of HK$2.804 billion and a net asset value per unit of HK$77.99.
On 30 September 2026, ACROBIOSYSTEMS (301080.SZ) filed for a Main Board listing on HKEX, with China Merchants Securities (HK) as sole sponsor.
On 30 September 2026, Amicro Technology passed the HKEX listing hearing, with China Securities International and Guotai Junan International as joint sponsors.
On 1 October 2026, PHANCY (06682.HK) terminated its subscription agreement for new shares of Huanxi Media (01003.HK) as conditions precedent were unmet; the subscription will not proceed.
On 30 September 2026, the CSRC issued supplementary filing requirements to five companies pursuing Hong Kong listings, covering capital and compliance.
On 30 September 2026, AMLOGIC (688099.SH) completed CSRC filing for up to 53,815,500 shares to be listed on HKEX, under a notice dated 24 August 2026.
On 30 September 2026, TGOOD (300001.SZ) said it received a CSRC filing notice for an H-share offering of up to 134,847,300 shares to be listed on HKEX.
On 29 September 2026, YUDO filed for an HKEX Main Board listing with CICC and CITIC Securities as joint sponsors. It is the world's largest HRS provider.
On 30 September 2026, CSPC PHARMA reported positive Phase III results for its GLP-1 receptor agonist Efmedaglutide Alfa Injection in type 2 diabetes.
On 30 September 2026, CHINA LONGYUAN (00916.HK) said it issued two 210-day ultra-short-term note tranches at a 1.35% coupon, raising RMB 3bn in total.
On September 30, 2026, the Hong Kong ETF market was dominated by biotech and healthcare themes. ChinaAMC Hang Seng Biotech ETF (3069.HK) led with a 4.01% gain; Global X China Biotech ETF, CSOP Hang Seng Biotech ETF and ChinaAMC Innovative Drugs all rose more than 3.2%, and six of the top ten gainers were biotech- or healthcare-related products. Japanese themes strengthened in tandem, and baijiu also performed. On the downside, STAR 50 themes pulled back, with Bosera STAR 50 Index ETF (2832.HK) falling 2.61% to lead the declines, while resources and technology themes weakened modestly. Among Southbound (Stock Connect) ETFs, biotech products led the gains, three products closed flat, and only two posted small declines.
On September 30, 2026, CAMSENSE rose 265.68% to top the gainers; Z.AI led liquidity with turnover of HKD 2.711 billion; TONGSHIFU and HUAYAN ROBOTICS saw their lock-ups released today.
